GlassScriptPhysician profile
Andrew Zurick
NPI 1942429816
$231,270.08
in general payments reported to CMS, 2019-2025
21 companies · $76K in 2025
The $76K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $14K · 2021: $17K · 2022: $14K · 2023: $10K · 2024: $79K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Travel and Lodging: $12K · Food and Beverage: $6,020 · Consulting Fee: $1,063 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,153.19 |
| Travel and Lodging | $11,794.23 |
| Food and Beverage | $6,019.60 |
| Consulting Fee | $1,062.50 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $127,696.85 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lantheus Medical Imaging, INC. | $67,302.68 | 2019-2024 | Definity |
| Heartflow, INC. | $19,737.09 | 2019-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $4,666.06 | 2020-2024 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $4,379.80 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,518.03 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,125.00 | 2019 | |
| Siemens Medical Solutions USA, INC. | $1,105.14 | 2023-2025 | Naeotom Alpha, Somatom Force |
| Amgen INC. | $1,089.35 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $1,014.63 | 2019-2025 | 2nd Gen Centrimag Primary Console |
| Agepha Pharma Fz LLC | $424.96 | 2024-2025 | Lodoco |
| Abiomed | $402.45 | 2021-2022 | |
| Ge Healthcare | $204.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $178.81 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $135.05 | 2020-2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $87.70 | 2019-2024 | Eliquis |
| Inspire Medical Systems, INC. | $75.42 | 2023-2024 | Inspire |
| Corcym INC | $55.52 | 2025 | Perceval |
| Pfizer INC. | $28.76 | 2019-2025 | |
| Boston Scientific Corporation | $24.21 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Zurick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.